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Abstract
Background: Population studies showed that patients with JAK2 V617F mutation had increased mortality, and
increased risk of any cancer, hematologic cancer, and myeloproliferative disease.
Case presentation: A 68-year-old Asian male with JAK2 V617F mutation developed four different hematologic and
non-hematologic neoplastic processes. In 2009, he was diagnosed with stage IA lung adenocarcinoma and also
noted to have worsening leukocytosis and thrombocytosis with peak platelet count of 1,054,000/mL). Bone marrow
biopsy was consistent with myeloproliferative neoplasm. His monocyte percentage increased in 2011 and met
criteria for chronic myelomonocytic leukemia. In 2013, he was admitted for proximal small bowel obstruction, with
biopsy confirming stage IE diffuse large B-cell lymphoma. In 2014, a bone marrow biopsy performed for worsening
leukocytosis was consistent with acute myeloid leukemia with monocytic differentiation.
Conclusion: This is a rare case depicting the association of JAK2 V617F mutation with myeloproliferative,
lymphoproliferative and solid neoplasms.
Keywords: Case report, Lung adenocarcinoma, Myeloproliferative neoplasm, Chronic myelomonocytic leukemia,
Diffuse large B-cell lymphoma, Acute myeloid leukemia, JAK2 V617F
Background
Myeloproliferative neoplasm (MPN) and chronic myelo-
monocytic leukemia (CMML) have the potential to
progress into acute myeloid leukemia (AML), and some
data also suggests an association between myeloprolifera-
tive and lymphoproliferative neoplasms (LPN's). In this
article, we describe a patient with JAK2 V617F mutation
who developed 4 different neoplastic processes: adenocar-
cinoma of the lung, MPN/CMML, diffuse large B-cell
lymphoma (DLBCL), acute myeloid leukemia with mono-
cytic differentiation (AML-M5). The patient also had a
translocation of chromosome 4 and 11, which is only seen
in a few case reports in therapy-related AML's following
exposure to topoisomerase II inhibitors [1]. He received
doxorubicin, a topoisomerase II inhibitor, as part of chemo-
therapy regimen for his DLBCL approximately 6-9 months
prior to the diagnosis of AML-M5. What is even more
intriguing about this case is the fact that the patient had a
JAK2 V617F mutation, which has been reported to be asso-
ciated with an increased risk of cancer and mortality [2].
The coexistence of four hematologic and non-hematologic
disorders in the same patient with JAK2 V617F mutation is
very rare, and we review here the literature on the associ-
ation of these processes.
Case presentation
A 68-year-old Asian male has significant medical history of
hypertension, chronic obstructive pulmonary disease, cor-
onary artery disease requiring percutaneous coronary inter-
vention, right lower extremity deep venous thrombosis/
pulmonary embolism and peripheral vascular disease. The
patient was a former long-time smoker but quitted cigarette
smoking about 20 years ago. His family history was non-
contributory. In 2009, patient was diagnosed with stage IA
adenocarcinoma of the lung (Fig. 1), and he underwent a
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video-assisted thoracoscopic left upper lobe segmentect-
omy. At the same time, he was noted to have worsening
leukocytosis and thrombocytosis. A complete blood count
(CBC) at the time showed white blood cell count (WBC)
28,500/μL with a neutrophil predominance of 86.2 %, a
hemoglobin of 14.7 gm/dL, and a platelet count of 737,000/
mL. The patient was found to be JAK2 V617F mutation
positive and BCR/ABL negative in his peripheral blood. At
one point, his platelet count peaked at 1,054,000/mL. A
bone marrow biopsy in October 2010 demonstrated
markedly hypercellular marrow with marked megakaryo-
cytes and mild myeloid hyperplasia consistent with MPN
(Fig. 2). The patient was started on hydroxyurea with close
monitoring of the blood counts. Of note, since around
April 2011, patient's white blood cell monocyte percentage
persistently ranged between 20-40 % and the absolute
monocyte count ranged between 2,000/μL and 5,000/μL,
meeting the criteria for CMML [3]. His thrombocytosis had
markedly improved by that time.
In December 2013, the patient was admitted for proximal
small bowel obstruction after presenting with multiple
episodes of bloody bowel movements and abdominal pain.
An esophagogastroduodenoscopy revealed erythematous
and thickened duodenal folds. Biopsy was consistent with
DLBCL (Fig. 3) and patient was staged as stage IE. Bone
marrow biopsy in January 2014 did not show evidence of
lymphoma but did show hypercellular marrow with
myeloid hyperplasia with left shift and trilineage dyspoiesis
and increased kappa restricted clonal plasma cells by flow
cytometry (1 %). Given this new lymphoma diagnosis,
hydroxyurea was held and chemotherapy with R-CHOP
(rituximab, cyclophosphamide, doxorubicin, vincristine,
prednisone) for 6 cycles were administered and completed
in May 2014. His course was complicated by respiratory
symptoms (coughing, shortness of breath) with pulmonary
infiltrates and hilar/mediastinal lymphadenopathy noted on
imaging and positive acid-fast bacillus culture for mycobac-
terium avium intracellulare (MAI). Fine-needle aspiration
of lymph nodes showed reactive bronchial cells.
In September 2014, the patient was noted to have a WBC
of 57,800/μL (manual differentiation showing 68 % neutro-
phils, 4 % bands, 3 % metameylocytes, 3 % myelocytes, 2 %
Fig. 1 H&E stain of the patient's lung adenocarcinoma specimen
under 20x magnification
Fig. 2 H&E stain of the patient's bone marrow biopsy consistent
with MPN under 40x magnification
Fig. 3 CD20 immunostain of the patient's small bowel biopsy
consistent with DLBCL
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lymphocytes, 8 % promonocytes, 10 % monocytes, 2 %
basophils), a hemoglobin of 11.8 gm/dL, and a platelet
count of 243,000/mL. Given these findings, a bone marrow
biopsy was performed, which demonstrated hypercellularity
approaching 100 %. There was a prominent population of
mature and immature/atypical monocytes comprising 77 %
of analyzed WBC. These cells uniformly expressed CD11c,
CD13, CD33 and CD64, with partial aberrant CD56 and
variable HLA-DR consistent with left-shifted/dyspoietic
maturation. These findings were consistent with acute mye-
loid leukemia with monocytic differentiation (AML-M5)
(Fig. 4). CD34 positive myeloblasts comprised 1-2 % of
cells. There was no evidence of lymphoma. Cytogenetics
showed 2 of 22 metaphases had translocation of chromo-
some 4 and 11, loss of chromosome 9, and an additional
copy of chromosome 11. Mixed lineage leukemia (MLL)
gene rearrangement was noted in 57.5 % of cells. Nucleo-
phosmin1 (NPM1) and FMS-like tyrosine kinase-3 (FLT-
3) mutations were not sent as the cytogenetics placed him
in the high risk AML category.
The patient was subsequently admitted in September
2014 for initiation of induction chemotherapy and
considerations for allogeneic stem cell transplantation.
At the time of admission, he reported night sweats
and nonspecific weight loss for a few weeks. He was
started on standard "7 + 3" induction chemotherapy
with idarubicin 12 mg/m2 on days 1-3 and cytarabine
100 mg/m2 on days 1-7. His course was complicated
by tumor lysis syndrome, cytopenias, and elevated
liver enzymes. A repeat bone marrow biopsy after
induction therapy in October 2014 was performed,
which unfortunately showed hypercellular marrow
90 % with 13 % promonocytes/monoblasts, consistent
with residual acute myeloid leukemia with monocytic
differentiation. Between November and December
2014, patient had received 2 cycles of decitabine while
a search for a match-unrelated donor was going on.
In January 2015, the patient developed symptoms of
hyperviscosity from thrombocytosis with a platelet count
greater than two million. He underwent thrombocyta-
pheresis with an improvement in platelet count and
symptoms. In March 2015, patient was admitted again
with thrombocytosis to platelet count over two million.
He was started on hydroxyurea to control his counts,
then received haploidentical allogeneic stem cell trans-
plant from his daughter with fludarabine/melphalan/
anti-thymocyte globulin conditioning. His course was
complicated by neutropenic sepsis, acute kidney and
liver injuries, gastrointestinal bleed, atrial fibrillation,
cardiomyopathy, volume overload and skin graft-versus-
host disease. In July 2015, repeat engraftment studies
showed only 9 % donor engraftment. His subsequent
decreasing blood counts and monocytosis confirmed on
flow cytometry were also consistent with leukemia
relapse. The patient expired in September 2015 while he
was on best supportive care alone.
Discussion
MPN's (previously chronic myeloproliferative diseases) are
characterized by effective clonal myeloproliferation (for
example, peripheral blood granulocytosis, thrombocytosis
or erythrocytosis) in the absense of dyserythropoiesis,
granulocytic dysplasia or monocytosis. Based on the 2008
World Health Organization Classification Scheme, MPN's
are further subdivided into "classical" (which includes
chronic myelogenous leukemia (CML), polycythemia vera
(PV), essential thrombocythemia (ET), primary mye-
lofibrosis (PMF)) and "atypical" subgroups. The patient
presented here met the criteria for ET, which is charac-
terized by megakaryocyte proliferation with large and
mature morphology associated with thrombocytosis in the
absence of reactive thrombocytosis. Demonstration of
JAK2 V617F mutation or other clonal marker is often
helpful in making the diagnosis [4, 5].
As a group, MPN's have been associated with disease
transformation to myelodysplasias (MDS) and/or acute
myeloid leukemia (AML). The reported incidence of
AML in patients with MPN's varies typically between 5-
10 % depending on the specific type of MPN after
10 years of observation [6, 7]. This risk seems to be
related to the underlying disease mechanism itself, but
can also be due to therapy for disease treatment.
Population-based data from Sweden showed that
patients with MPN's who received radioactive phosphorus
(P(32)) greater than 1,000 MBq and alkylating agents
greater than 1 gram had a 4.6-fold (95 % CI, 2.1-9.8;
Fig. 4 H&E stain of the patient's bone marrow biopsy consistent
with AML-M5 under 40x magnification
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P = 0.002) and 3.4-fold (95 % CI, 1.1-10.6; P = 0.015)
increased risk of AML/MDS, respectively. Of note, 41
(25 %) of 162 patients with MPN's with AML/MDS
development were never exposed to alkylating agents,
P32 or hydroxyurea, suggesting a major role in non-
treatment related factors [8].
Recent studies have also demonstrated an association
between MPN's and LPN's. An Italian study reported that
patients with MPN's had a 3.44-fold increased risk of
developing LPN's compared with the general population,
ranging from 2.86 for plasma cell disorders, 3.44 for non-
Hodgkin's lymphoma, to 12.42 for chronic lymphocytic
leukemia. The risk of developing non-Hodgkin's lym-
phoma was substantially increased to 5.71-fold in the
presence of a JAK2 V617F mutation [9].
The patient was initially diagnosed with a JAK2 posi-
tive MPN, but subsequently developed monocytosis
while his thrombocytosis improved. He met the World
Health Organization criteria for CMML, which is de-
fined as having > 10 % of the entire white blood cell
differential, an absolute monocyte count >1,000/μL,
absent BCR-ABL1 fusion gene, < 20 % myeloblasts,
monoblasts and promonocytes, and dysplasia in one or
more myeloid lineages [3]. CMML has both myeloprolif-
erative and myelodysplastic features, and therefore is
classified as a myelodysplastic syndrome/myeloprolifera-
tive neoplasm (MDS/MPN) [10]. The median age at
diagnosis is around 70 years of age, with a 2:1 male
predominance [11]. The pathogenesis of CMML is also
not entirely clear. Current approaches suggested that
there might be preferred order of somatic genetic muta-
tions: TET2 or ASXL1 first, SRSF2 or an alternative
splice gene second, then a signaling gene mutation in-
ducing GM-CSF hypersensitivity and myeloproliferation
in 35-40 % of cases [12].
The patient subsequently developed AML-M5. Cytogen-
etic studies demonstrated translocation (4;11)(q21;q24),
monosomy 9 and trisomy 11. MLL gene rearrangement,
which involves the chromosome band 11q23, was noted in
57.5 % of the abnormal myeloid cells. In general, chromo-
some abnormalities of the same types seen in primary
AML are also seen in therapy-related AML/MDS [13]. It
has been described in the literature that deletions or loss of
chromosome arm 5q or 7q or loss of the entire chromo-
some (5q-/-5 and 7q-/-7) can be seen in AML/MDS after
treatment with alkylating agents, whereas balanced aberra-
tions with a rearrangement are characteristic of that related
to topoisomerase II inhibitors. These balanced chromo-
somal aberrations include the MLL, AML1/CBFB, RARA,
or NUP98 genes [14]. The MLL gene is highly conserved
among species and is associated with "mixed-lineage"
leukemia, where blast cells display both myeloid and
lymphoid characteristics. While myeloid and lymphoid
phenotypes are evenly distributed among de novo leukemia
cases with these abnormalities, the vast majority (>90 %) of
therapy-related AML are associated with the myeloid
phenotype. Topoisomerase II inhibitors, such as the anthra-
cyclines (e.g., doxorubicin), mitoxantrone and dactinomycin
have been associated with MLL gene rearrangement, which
typically has a latency period of median 30-34 months [15].
It should be noted that the MLL gene rearrangement itself
cannot definitively rule out de novo AML. In one study, the
incidence of AML with MLL gene rearrangement was
noted to be 9.4 % in therapy-related AML vs. 2.6 % in de
novo AML (P < 0.001) [16]. Given our patient's long history
of MPN/CMML and his AML developing within 8 months
following the use of doxorubicin with a distinct cytogenetic
profile and MLL gene rearrangement, this is more suggest-
ive of AML related to either MPN/CMML, although prior
anthracycline use may play a role as well.
As noted, our patient was discovered to have a JAK2
V617F mutation while undergoing workup for MPN/
CMML. The JAK2 V617F mutation has long been de-
scribed as dominant gain-of-function mutation that
contributes to the expansion of MPN clones. It is not
only important in the diagnosis of MPN's, but is also
associated with a significantly longer duration of disease
and a higher rate of complications [17]. While this
mutation is present in the majority of patients with
MPN's, it has also been seen in the peripheral blood of
healthy donors, with the percentage quoted to range
between 1-10 % depending on the assay used [18, 19].
The significance of the mutation in this setting is
unclear. However, in a Danish study, out of 10,507
participants were screened for the presence of JAK2
V617F and followed for up to 17.6 years after blood
sampling. Prevalence of the mutation in this predomin-
antly Caucasian population was 0.2 % (n = 18). Partici-
pants with the mutation were associated with increased
mortality, corresponding to a multifactorially adjusted
hazard ratio of 3.0 (95 % CI, 1.9-4.9). The multi-
factorially adjusted hazard ratios for any cancer and
hematologic cancer were 3.7 (95 % CI, 1.7-8.0) and 58
(95 % CI, 13-261), respectively [2]. Thus, the results of
this study suggests that the presence of the JAK2 V617F
mutation may be a marker for increased risk of develop-
ing future malignancies and increased mortality.
Conclusion
In this report, we presented a case in which a patient
with a JAK2 V617F mutation developed four different
hematologic and non-hematologic neoplastic processes:
lung adenocarcinoma, MPN/CMML, DLBCL, and AML-
M5. While the causality between JAK2 mutation and the
various malignancies cannot be established in this case,
we believe that this is not a mere coincidence and
that the presence of JAK2 mutation is associated with
the subsequent development of both hematologic and
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non-hematologic malignancies [2]. Identification of down-
stream markers of JAK2 can potentially confirm causality,
although this was not performed as the extra information
would not have changed management at the time. During
the past decade, cancer-related gene mutation panels have
been increasingly used, with some mutations yielding po-
tential diagnostic, prognostic and therapeutic information
in various malignancies [20]. The case presented here is
one good example of how the presence of an activating
mutation may provide insight into the subsequent devel-
opment of neoplastic processes.
Based on data from the North American Association
of Central Cancer Registries (NAACCR), the average
annual age-adjusted incidence rates of MDS, MPN and
CMML are 3.3, 2.1 and 0.3 per 100,000 people. Based on
follow up data through 2004 from the Surveillance,
Epidemiology, and End Results (SEER) Program, the 3-
year relative survival (comparing observed survival with
expected survival from a set of people with the same
characteristics as the patient cohort) for MDS, MPN and
CMML are 45 %, 80 % and 21 % respectively [21]. Given
these statistics, there is a need for not only early recog-
nition of these disease entities, but also improvement in
therapeutics for this patient population. Further research
is necessary to determine the relationships among these
distinct yet closely related hematologic disorders and to
evaluate the significance of the JAK2 V617F mutation
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